{
    "root": "3417f51c-7ace-49a1-ab3e-d14de2384c71",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250228",
    "ingredients": [
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Anhydrous Dibasic Calcium Phosphate",
            "code": "L11K75P92J"
        },
        {
            "name": "Crospovidone",
            "code": "2S7830E561"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "rosuvastatin tablets indicated : \u2022 reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk cv disease based age , high-sensitivity c-reactive protein ( hscrp ) \u22652 mg/l , least one additional cv risk factor.\u2022 adjunct diet : \u00ba reduce low-density lipoprotein cholesterol ( ldl-c ) adults primary hyperlipidemia.\u00ba reduce ldl-c slow progression atherosclerosis adults.\u00ba reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . \u2022 adjunct diet treatment adults : \u00ba primary dysbetalipoproteinemia.\u00ba hypertriglyceridemia .",
    "contraindications": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin tablets modifications due . ( 2.6 )",
    "warningsAndPrecautions": "rosuvastatin tablets supplied : ndc 69434-005-02 : 5mg . round , yellow film coated tablet , biconvex , one side tablet debossed \u201c y16 \u201d , side smooth ; bottle 90 tablets.ndc 69434-005-03 : 5mg . round , yellow film coated tablet , biconvex , one side tablet debossed \u201c y16 \u201d , side smooth ; bottle 500 tablets . ndc 69434-006-02 : 10 mg. round , pink film coated tablet , biconvex , one side tablet debossed \u201c y17 \u201d , side smooth ; bottle 90 tablets.ndc 69434-006-03 : 10 mg. round , pink film coated tablet , biconvex , one side tablet debossed \u201c y17 \u201d , side smooth ; bottle 500 tablets . ndc 69434-007-02 : 20 mg. round , yellow film coated tablet , biconvex , one side tablet debossed \u201c y19 \u201d , side smooth ; bottle 90 tablets.ndc 69434-007-03 : 20 mg. round , yellow film coated tablet , biconvex , one side tablet debossed \u201c y19 \u201d , side smooth ; bottle 500 tablets . ndc 69434-008-01 : 40 mg. round , pink film coated tablet , biconvex , one side tablet debossed \u201c y20 \u201d , side smooth ; bottle 30 tablets.ndc 69434-008-03 : 40 mg. round , pink film coated tablet , biconvex , one side tablet debossed \u201c y20 \u201d , side smooth ; bottle 500 tablets . storage store controlled room temperature , 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "rosuvastatin tablets contraindicated following conditions : \u2022 acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . \u2022hypersensitivity rosuvastatin excipients rosuvastatin tablets . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin tablets [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated:\u2022 To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) \u22652 mg/L, and at least one additional CV risk factor.\u2022 As an adjunct to diet to:\u00ba Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.\u00ba Reduce LDL-C and slow the progression of atherosclerosis in adults.\u00ba Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\u2022 As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\u2022 As an adjunct to diet for the treatment of adults with:\u00ba Primary dysbetalipoproteinemia.\u00ba Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ROSUVASTATIN TABLETS, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for\u00a0ROSUVASTATIN TABLETS dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions_original": "Rosuvastatin\u00a0tablets are supplied as:\n                  NDC 69434-005-02: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed\u201cY16\u201d, the other side is smooth; bottle of 90 tablets.NDC 69434-005-03: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed \u201cY16\u201d, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-006-02: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed \u201cY17\u201d, the other side is smooth; bottle of 90 tablets.NDC 69434-006-03: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed \u201cY17\u201d, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-007-02: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed \u201cY19\u201d, the other side is smooth; bottle of 90 tablets.NDC 69434-007-03: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed \u201cY19\u201d, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-008-01: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed \u201cY20\u201d, the other side is smooth; bottle of 30 tablets.NDC 69434-008-03: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed \u201cY20\u201d, the other side is smooth; bottle of 500 tablets.\n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Rosuvastatin tablets are contraindicated in the following conditions:\n                  \u2022 Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                  \u2022Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with\u00a0rosuvastatin tablets\u00a0[see Adverse Reactions (6.1)]."
}